MX9301823A - COMPOSITION FOR THE SUPPLY OF CONTROLLED RELEASE OF A BIOLOGICALLY ACTIVE AGENT. - Google Patents

COMPOSITION FOR THE SUPPLY OF CONTROLLED RELEASE OF A BIOLOGICALLY ACTIVE AGENT.

Info

Publication number
MX9301823A
MX9301823A MX9301823A MX9301823A MX9301823A MX 9301823 A MX9301823 A MX 9301823A MX 9301823 A MX9301823 A MX 9301823A MX 9301823 A MX9301823 A MX 9301823A MX 9301823 A MX9301823 A MX 9301823A
Authority
MX
Mexico
Prior art keywords
biologically active
controlled release
composition
supply
active agent
Prior art date
Application number
MX9301823A
Other languages
Spanish (es)
Inventor
Wouter E Roorda
Fred Ehnow
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of MX9301823A publication Critical patent/MX9301823A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Partículas de liberación controladas que contienen agentes biológicamentes activos tales como fármacos terapéuticos y anestésicos locales que suspenden en un vehículo de suspensión líquido que tiene una viscosidad elevada, la viscosidad siendo substancialmente mayor que aquella del agua.Controlled release particles containing biologically active agents such as therapeutic drugs and local anesthetics that suspend in a liquid suspension vehicle having a high viscosity, the viscosity being substantially higher than that of water.

MX9301823A 1992-03-30 1993-03-30 COMPOSITION FOR THE SUPPLY OF CONTROLLED RELEASE OF A BIOLOGICALLY ACTIVE AGENT. MX9301823A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86052492A 1992-03-30 1992-03-30

Publications (1)

Publication Number Publication Date
MX9301823A true MX9301823A (en) 1994-01-31

Family

ID=25333409

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9301823A MX9301823A (en) 1992-03-30 1993-03-30 COMPOSITION FOR THE SUPPLY OF CONTROLLED RELEASE OF A BIOLOGICALLY ACTIVE AGENT.

Country Status (5)

Country Link
US (1) US5540912A (en)
AU (1) AU3941493A (en)
MX (1) MX9301823A (en)
WO (1) WO1993019739A1 (en)
ZA (1) ZA932272B (en)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922340A (en) 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
HUP9700322A3 (en) 1995-06-09 2001-03-28 Euro Celtique Sa Formulations and methods for providing prolonged local anesthesia
US5716631A (en) * 1995-09-29 1998-02-10 Rdn Therapeutics Inc. Long acting narcotic analgesics and antagonists
NZ505584A (en) * 1996-05-24 2002-04-26 Univ British Columbia Delivery of a therapeutic agent to the smooth muscle cells of a body passageway via an adventia
AU775787B2 (en) * 1996-05-24 2004-08-12 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing diseases of body passageways
AU2004202838B2 (en) * 1996-05-24 2008-05-29 Angiotech Pharmaceuticals Inc. Compositions and methods for treating or preventing diseases of body passageways
WO1997049391A1 (en) 1996-06-24 1997-12-31 Euro-Celtique, S.A. Methods for providing safe local anesthesia
US6046187A (en) 1996-09-16 2000-04-04 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
BR9815499A (en) * 1997-07-02 2001-01-02 Euro Celtique Sa Prolonged anesthesia in joints and body spaces.
ES2359973T3 (en) * 1998-03-19 2011-05-30 MERCK SHARP & DOHME CORP. LIQUID POLYMER COMPOSITIONS FOR THE CONTROLLED RELEASE OF BIOACTIVE SUBSTANCES.
US6451335B1 (en) 1998-07-02 2002-09-17 Euro-Celtique S.A. Formulations and methods for providing prolonged local anesthesia
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) * 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
WO2000064528A1 (en) 1999-04-28 2000-11-02 Situs Corporation Drug delivery system
US6730313B2 (en) * 2000-01-25 2004-05-04 Edwards Lifesciences Corporation Delivery systems for periadventitial delivery for treatment of restenosis and anastomotic intimal hyperplasia
US6613355B2 (en) 2000-05-11 2003-09-02 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
US20050042194A1 (en) 2000-05-11 2005-02-24 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
ATE377048T1 (en) * 2000-09-06 2007-11-15 Ap Pharma Inc DEGRADABLE POLYACETAL POLYMERS
US6726898B2 (en) 2000-11-17 2004-04-27 Gary R. Jernberg Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
US6576226B1 (en) 2000-11-17 2003-06-10 Gary R. Jernberg Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
EP1363602A4 (en) * 2001-01-25 2006-01-11 Euro Celtique Sa Local anesthetic, and method of use
US7119062B1 (en) 2001-02-23 2006-10-10 Neucoll, Inc. Methods and compositions for improved articular surgery using collagen
US6590059B2 (en) * 2001-05-11 2003-07-08 Ap Pharma, Inc. Bioerodible polyorthoesters from dioxolane-based diketene acetals
US20030152630A1 (en) * 2001-05-11 2003-08-14 Ng Steven Y. PEG-POE, PEG-POE-PEG, and POE-PEG-POE block copolymers
US6702744B2 (en) * 2001-06-20 2004-03-09 Advanced Cardiovascular Systems, Inc. Agents that stimulate therapeutic angiogenesis and techniques and devices that enable their delivery
US7968119B2 (en) * 2001-06-26 2011-06-28 Farrell John J Tamper-proof narcotic delivery system
CN1703197A (en) * 2001-11-14 2005-11-30 阿尔扎有限公司 Injectable depot compositions and uses thereof
JP2005519873A (en) * 2001-11-14 2005-07-07 アルザ・コーポレーション Catheter injectable depot compositions and their use
US20070196415A1 (en) * 2002-11-14 2007-08-23 Guohua Chen Depot compositions with multiple drug release rate controls and uses thereof
US6524606B1 (en) * 2001-11-16 2003-02-25 Ap Pharma, Inc. Bioerodible polyorthoesters containing amine groups
US8608661B1 (en) 2001-11-30 2013-12-17 Advanced Cardiovascular Systems, Inc. Method for intravascular delivery of a treatment agent beyond a blood vessel wall
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US7361368B2 (en) * 2002-06-28 2008-04-22 Advanced Cardiovascular Systems, Inc. Device and method for combining a treatment agent and a gel
ES2319400T3 (en) * 2002-07-31 2009-05-07 Durect Corporation COMPOSITIONS INJECTABLE DEPOSIT AND USE OF THE SAME.
DK1539101T3 (en) * 2002-07-31 2009-04-27 Alza Corp Injectable, multi-modal polymeric compositions and applications thereof
FR2846557B1 (en) * 2002-10-30 2007-06-08 Statice Sante IMPLANTABLE STRUCTURE FOR PROLONGED AND CONTROLLED RELEASE OF AN ACTIVE INGREDIENT
US7045589B2 (en) * 2002-11-15 2006-05-16 A.P. Pharma, Inc. Bioerodible poly(ortho esters) from dioxane-based di(ketene acetals), and block copolymers containing them
CA2508722A1 (en) * 2002-12-11 2004-06-24 Pfizer Products Inc. Controlled-release of an active substance into a high fat environment
ATE482695T1 (en) * 2002-12-13 2010-10-15 Durect Corp ORAL DOSAGE FORM WITH HIGH VISCOSITY LIQUID CARRIER SYSTEMS
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US8821473B2 (en) 2003-04-15 2014-09-02 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
US8038991B1 (en) 2003-04-15 2011-10-18 Abbott Cardiovascular Systems Inc. High-viscosity hyaluronic acid compositions to treat myocardial conditions
US8383158B2 (en) 2003-04-15 2013-02-26 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
US20060045891A1 (en) * 2004-08-24 2006-03-02 Lovalenti Phillip M Density-matched suspension vehicles and pharmaceutical suspensions
LT2767292T (en) * 2004-09-17 2016-12-12 Durect Corporation Sustained Local Anesthetic Composition Containing SAIB
EP2444071A1 (en) * 2004-09-27 2012-04-25 Sigmoid Pharma Limited Minicapsule formulations
CN101119713A (en) * 2004-11-24 2008-02-06 阿尔高克斯制药公司 Capsaicinoid gel formulation and uses thereof
US20060142234A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
NZ552862A (en) * 2005-03-15 2009-03-31 Animal Ethics Pty Ltd A topical analgesic composition
US8303972B2 (en) 2005-04-19 2012-11-06 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
US20080125745A1 (en) 2005-04-19 2008-05-29 Shubhayu Basu Methods and compositions for treating post-cardial infarction damage
US8828433B2 (en) 2005-04-19 2014-09-09 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
US9539410B2 (en) 2005-04-19 2017-01-10 Abbott Cardiovascular Systems Inc. Methods and compositions for treating post-cardial infarction damage
US8187621B2 (en) 2005-04-19 2012-05-29 Advanced Cardiovascular Systems, Inc. Methods and compositions for treating post-myocardial infarction damage
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US8362086B2 (en) 2005-08-19 2013-01-29 Merial Limited Long acting injectable formulations
US20070148248A1 (en) 2005-12-22 2007-06-28 Banner Pharmacaps, Inc. Gastric reflux resistant dosage forms
US20070264339A1 (en) * 2006-05-12 2007-11-15 Ap Pharma, Inc. Base-stabilized polyorthoester formulations
US20070265329A1 (en) * 2006-05-12 2007-11-15 Devang Shah T Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
US20070264338A1 (en) * 2006-05-12 2007-11-15 Shah Devang T Base-stabilized polyorthoester formulations
CA2651855C (en) 2006-05-30 2011-08-02 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US7732190B2 (en) 2006-07-31 2010-06-08 Advanced Cardiovascular Systems, Inc. Modified two-component gelation systems, methods of use and methods of manufacture
ES2422864T3 (en) 2006-08-09 2013-09-16 Intarcia Therapeutics, Inc Osmotic release systems and piston units
US9242005B1 (en) 2006-08-21 2016-01-26 Abbott Cardiovascular Systems Inc. Pro-healing agent formulation compositions, methods and treatments
DK2117521T3 (en) 2006-11-03 2012-09-03 Durect Corp TRANSDERMAL ADMINISTRATION SYSTEMS INCLUDING BUPIVACAIN
US8741326B2 (en) 2006-11-17 2014-06-03 Abbott Cardiovascular Systems Inc. Modified two-component gelation systems, methods of use and methods of manufacture
US9005672B2 (en) 2006-11-17 2015-04-14 Abbott Cardiovascular Systems Inc. Methods of modifying myocardial infarction expansion
US8192760B2 (en) 2006-12-04 2012-06-05 Abbott Cardiovascular Systems Inc. Methods and compositions for treating tissue using silk proteins
PT2157967E (en) 2007-04-23 2013-04-03 Intarcia Therapeutics Inc Suspension formulations of insulinotropic peptides and uses thereof
DK2170283T3 (en) 2007-06-22 2019-04-15 Univ Texas CREATION OF STABLE SUBMICRON Peptide OR PROTEIN PARTICLES BY THIN FILM FREEZING
AU2008335809A1 (en) * 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
US8038721B2 (en) * 2007-12-17 2011-10-18 Anna Love Soft tissue filler
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
US9132085B2 (en) * 2008-04-18 2015-09-15 Warsaw Orthopedic, Inc. Compositions and methods for treating post-operative pain using clonidine and bupivacaine
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
JP5711138B2 (en) 2008-11-16 2015-04-30 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム High concentration low viscosity suspension
JP2012512163A (en) * 2008-12-11 2012-05-31 エーピー ファーマ， インコーポレイテッド Methods for enhancing the stability of polyorthoesters and their formulations
KR101823699B1 (en) 2009-09-28 2018-01-30 인타르시아 세라퓨틱스 인코포레이티드 Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
TW201521769A (en) 2013-03-15 2015-06-16 Durect Corp Compositions with a rheological modifier to reduce dissolution variability
JP6564369B2 (en) 2013-12-09 2019-08-21 デュレクト コーポレイション Pharmaceutically active agent conjugates, polymer conjugates, and compositions and methods involving them
CA2950311C (en) 2014-06-23 2019-05-14 Banner Life Sciences Llc All natural enteric soft capsules comprising active ingredients
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP3265064A4 (en) * 2015-03-04 2018-11-07 Microvention, Inc. Drug delivery device
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
KR102574993B1 (en) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
US20190350867A1 (en) * 2016-12-27 2019-11-21 Soon Kap Hahn Prevention of local tumor recurrence following surgery using sustained and/or delayed release of medicaments contained in micro-particles
KR20190104039A (en) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Methods Including Continuous Administration of GLP-1 Receptor Agonists and Co-administration of Drugs
AU2018345844B2 (en) 2017-10-06 2024-03-07 Foundry Therapeutics, Inc. Implantable depots for the controlled release of therapeutic agents
BR112022013784A2 (en) 2020-01-13 2022-10-11 Durect Corp DISTRIBUTION SYSTEMS FOR PROLONGED RELEASE DRUGS WITH REDUCED IMPURITIES AND RELATED METHODS

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351337A (en) * 1973-05-17 1982-09-28 Arthur D. Little, Inc. Biodegradable, implantable drug delivery device, and process for preparing and using the same
US4093709A (en) * 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4131648A (en) * 1975-01-28 1978-12-26 Alza Corporation Structured orthoester and orthocarbonate drug delivery devices
US4180646A (en) * 1975-01-28 1979-12-25 Alza Corporation Novel orthoester polymers and orthocarbonate polymers
US4070347A (en) * 1976-08-16 1978-01-24 Alza Corporation Poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers having carbonyloxy functionality
US4122158A (en) * 1976-09-23 1978-10-24 Alza Corporation Topical therapeutic preparations
US4249531A (en) * 1979-07-05 1981-02-10 Alza Corporation Bioerodible system for delivering drug manufactured from poly(carboxylic acid)
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
IT1183574B (en) * 1985-05-08 1987-10-22 Eurand Spa METHOD FOR OBTAINING A HOMOGENEOUS ETHERPORARY SUSPENSION OF MICROCAPS
US4780320A (en) * 1986-04-29 1988-10-25 Pharmetrix Corp. Controlled release drug delivery system for the periodontal pocket
US4919939A (en) * 1986-04-29 1990-04-24 Pharmetrix Corporation Periodontal disease treatment system
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
JPS63122620A (en) * 1986-11-12 1988-05-26 Sanraku Inc Polylactic acid microsphere and production thereof
US4917892A (en) * 1988-06-28 1990-04-17 Temple University Encapsulated topical delivery system
ES2062634T3 (en) * 1990-08-30 1994-12-16 Senju Pharma Co COMPOSITION WITH CONTROLLED RELEASE OF THE PHARMACY.
US5332576A (en) * 1991-02-27 1994-07-26 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
AU2154892A (en) * 1991-05-07 1992-12-21 Dynagen, Inc. A controlled, sustained release delivery system for treating drug dependency

Also Published As

Publication number Publication date
AU3941493A (en) 1993-11-08
WO1993019739A1 (en) 1993-10-14
US5540912A (en) 1996-07-30
ZA932272B (en) 1993-10-19

Similar Documents

Publication Publication Date Title
MX9301823A (en) COMPOSITION FOR THE SUPPLY OF CONTROLLED RELEASE OF A BIOLOGICALLY ACTIVE AGENT.
ES2177592T3 (en) BIOCOMPATIBLE AND BIODEGRADABLE NANOPARTICLES FOR THE ABSORPTION AND ADMINISTRATION OF PROTEINIC MEDICINES.
ES2055677T3 (en) COMPOSITION FOR THE TREATMENT OF ERECTILE DYSFUNCTION.
ES2062632T3 (en) HAIR TREATMENT COMPOSITION.
BR0107869A (en) Electrogenated pharmaceutical compositions
BR0014929A (en) Drug delivery device, and process for delivering a pharmaceutically active agent to a target tissue within a body
ES2137350T3 (en) PHARMACEUTICAL FORMULATION.
ES2181315T3 (en) MEMBERS STRATIFIED TO CONTROL THE ADMINISTRATION REGIME FOR USE IN ELECTRICAL TRANSPORTATION DEVICES.
MX167175B (en) DRUG DELIVERY SYSTEM, WITH CONTROLLED RELEASE, FOR PERIODONTAL BAG
ES2124791T3 (en) RELEASE COMPOSITION IN THE LYMPHATIC SYSTEM OF AN ACTIVE AGENT.
MX166018B (en) ELECTRICAL SYSTEM OF TRANSDERMIC DRUG APPLICATOR
BR9811381A (en) Processes for treating a mammalian organism to obtain a desired local or systemic physiological or pharmacological effect, for treating a mammalian organism for cytomegalovirus retinitis, to provide controlled and prolonged administration of an agent effective in obtaining a desired physiological or local or systemic pharmacological, and, prolonged release drug delivery system
GT199900151A (en) DRUG CONTROLLED DELIVERY SYSTEM ORALALLY ADMINISTERED, PROVIDING TEMPORARY AND SPACE CONTROL.
MX9202407A (en) PHARMACEUTICAL COMPOSITION CONTAINING AN ALYLAMINE COMPOUND AS THE ACTIVE AGENT AND PROCESS FOR ITS PREPARATION.
ES2110963T3 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PAIN ASSOCIATED WITH HESPESZOSTER AND POST-HERPETIC NEURALGIA BY TOPIC APPLICATION OF LOCAL ANESTHETICS.
AR006484A1 (en) PHARMACEUTICAL COMPOSITION WITH ANESTHETIC EFFECT, USE OF THIS COMPOSITION FOR THE MANUFACTURE OF MEDICINES, AND PROCESS FOR THE MANUFACTURE OF THIS COMPOSITION.
DOP2001000229A (en) HYDROGEL ACTIVATED DRUG DOSAGE FORM
ES2044912T3 (en) PHARMACEUTICAL COMPOSITIONS EQUIPPED WITH SEQUESTRATING ACTIVITY FOR BILIARY ACIDS, CONTAINING CHOLESTIRAMINE AS AN ACTIVE SUBSTANCE, AND PROCEDURE FOR ITS PREPARATION.
BR9917074A (en) Cosmetic or pharmaceutical composition of the oil-in-water emulsion type comprising a micronized biologically active agent and an appropriate emulsifying system and cosmetic treatment process
ES2139002T3 (en) CYTOTOXIC DRUG THERAPY.
BR9306254A (en) Fluid distributor
ES2178048T3 (en) USE OF RIFAXIMINE AS A MEDICINAL PRODUCT FOR THE TREATMENT OF DIARRHEA BY CRYPTOSPORIDIOSIS.
ES2082831T3 (en) COMPOSITION FOR TREATMENT OF TISSUES WITH SOFTENING PROPERTIES.
PT706385E (en) USE OF ISOVALERAMIDE AS A SOFT ANSIOLITIC AGENT AND AS SOFT SEDATIVE AGENT
ATE361772T1 (en) CONTAINER FOR IONTOPHORETIC ADMINISTRATION OF MEDICATIONS WITH INERT MATERIAL COMPONENTS

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees